Navigation Links
CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
Date:3/14/2012

CAMBRIDGE, Mass., March 14, 2012 /PRNewswire-iReach/ -- CELEXION LLC today announced the issuance of US Patent number 8,133,704 by the US Patent and Trademark Office entitled "Biological synthesis of difunctional alkanes from carbohydrate feedstocks."  The patent was issued on March 13, 2012 and covers biological methods of converting renewable feedstocks into a variety of high-value chemicals with a total market value of over $10B.

"At CELEXION, we leverage the power of biological systems to make new, high performance products and to make everyday products more functional, affordable, and sustainable," said Dr. Brian M. Baynes, CEO of CELEXION and co-inventor of the technology.  "The methods disclosed in this patent enable a variety of important bulk chemicals to be synthesized from renewable starting materials using biological catalysts.  The efficiency of this approach makes our products not only sustainable, but also less expensive than their petroleum-derived equivalents."

Claims of the '704 patent include key biosynthetic steps from common metabolic intermediates and their uses in manufacturing a family of chemicals including adipic acid, caprolactam, hexamethylenediamine, pimelic acid, and caprolactone.  These chemicals are key components in a wide variety of packaging, materials, polymers, and other industrial and consumer applications.

About CELEXION
CELEXION LLC is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company's technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA.  CELEXION is headquartered in Cambridge, MA, USA.  For further information, please visit our website at www.celexionbio.com.

CELEXION and SECANT are registered trademarks of Celexion LLC.

Media Contact: Celexion Business Development, Celexion LLC, +1-617-500-3011 x1, info@celexionbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CELEXION LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chemring Detection Systems Awarded $9M for Biological Detection Systems
2. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
3. Chemring Detection Systems Awarded $500k for Strategic Research and Development
4. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
5. Sloan Research Fellowships Awarded to 126 Young Scholars
6. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
7. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
11. BioPower Systems Awarded $5 Million from Victorian Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):